Nav: Home

Results from the BIONICS trial reported at TCT 2016

October 30, 2016

WASHINGTON - October 30, 2016 - The large multinational randomized BIONICS study found that a novel ridaforolimus-eluting stent (BioNIR) was non-inferior to a zotarolimus-eluting stent (Resolute) for one-year clinical outcomes in a broad, less selected 'more comers' population. Results of this trial will be submitted to the FDA for U.S. approval of this novel drug-eluting stent.

Findings were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The ridaforolimus-eluting stent is a thin-strut (90 μm) cobalt chromium stent that elutes the rapamycin analogue ridaforolimus from a durable elastomeric polymeric coating. The multicenter randomized trial was conducted at 76 medical centers in the U.S., Canada, Europe, and Israel and enrolled a broad range of patients with coronary artery disease including patients with Non-ST Elevation MI (NSTEMI) as well as complex lesions. The primary endpoint was target lesion failure (TLF) at one year, the composite rate of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia driven target lesion revascularization (ID-TLR). Secondary endpoints were one year major adverse cardiovascular events (MACE), target vessel failure (TVF) and individual component endpoints, definite/probable stent thrombosis and procedural success.

A total of 1,919 patients were randomized 1:1 to the BioNIR ridaforolimus-eluting stent (n= 958, 1,275 lesions) or Resolute zotarolimus-eluting stent (n=961, 1,277 lesions) stent. The baseline clinical characteristics were well balanced between the two arms, as were angiographic baseline characteristics with the exception of severe calcification (13.3% in the BioNIR group vs. 10.5% in the Resolute group, P=0.03).

The primary endpoint of TLF at one year was identical for both at 5.3% (P=0.98). In addition, the rates of cardiac death (0.5% vs. 0.2%, P=0.29), TV-MI (3.1% vs. 3.3%, P=0.81) and ID-TLR (3.0% vs. 2.4%, P=0.38) were similar. Definite/probable stent thrombosis was 0.4% (4/921) for the ridaforolimus-eluting stent

and 0.6% (6/927) for the zotarolimus-eluting stent (P=0.75). Device success was 98.3% for the ridaforolimus-eluting compared to 99.5% for the zotarolimus-eluting stent (P=0.004).

"One-year clinical outcomes from the BIONICS study clearly show that the ridaforolimus-eluting stent was non-inferior to the zotarolimus-eluting stent with identical target lesion failure rates," said principal investigator, David E. Kandzari, MD. Dr. Kandzari is Director of Interventional Cardiology and Chief Scientific Officer at the Piedmont Heart Institute in Atlanta, GA. "In addition, it had a low stent thrombosis rate with no events beyond 30 days."

The BIONICS trial was funded by Medinol and designed and conducted by the CRF Clinical Trials Center in collaboration with Novella Clinical which provided site management. Dr. Kandzari reported grant or research support from Abbott Vascular, Boston Scientific, Medtronic, Biotronik, St. Jude Medical/Thoratec, and Ablative Solutions, and consulting fees/honoraria from Boston Scientific, Medtronic, Micell Technologies, and St. Jude Medical.

The results of the BIONICS Trial will be presented on Sunday, October 30 at 9:40 AM ET in the Main Arena (Ballroom, Level 3) of the Walter E. Washington Convention Center.
-end-
About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Cardiac Death Articles:

New opioid use in older adults with COPD associated with increased risk of cardiac death
Older adults with COPD who recently started using opioids have an increased risk of coronary artery disease-related death compared to non-opioid users, researchers at St.
New report outlines 10 measures for the prevention of sudden cardiac death
A new report presents 10 quality and performance measures that are intended to help stakeholders--including health systems, legislative bodies, and nongovernmental organizations, as well as healthcare practitioners, patients, families and communities -- in the effort to prevent sudden cardiac death.
Sudden cardiac death of teen reminds physicians of precision medicine
The sudden death of a 13-year-old boy resulted in more than 20 relatives to be incorrectly diagnosed as having a potentially lethal heart rhythm condition.
Higher thyroid hormone levels linked to sudden cardiac death
The risk of sudden cardiac death was significantly greater in patients with thyroid hormone levels at the higher end of normal, compared to patients with levels at the low end.
Public health researchers develop model to predict Sudden Cardiac Death
Researchers from Emory's Rollins School of Public Health developed a sudden cardiac death (SCD) predictive model that can help identify and prevent the disease in individuals at high risk.
Penn medicine researchers predict sudden cardiac death risk
For the first time, a team of researchers led by Rajat Deo, MD, MTR, an assistant professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania, has developed and validated a prediction model to determine sudden cardiac death risk in adults without a history of cardiovascular disease (CVD).
Men may face high lifetime risk of sudden cardiac death
One in nine men may be at higher risk of premature death due to sudden cardiac death - usually with no warning.
Hypertrophic cardiomyopathy under-appreciated cause of sudden cardiac death in male minority athletes
Sudden deaths in young, seemingly healthy competitive athletes are tragic events.
Revealed: New insights on causes of sudden cardiac death in the young
Genetic testing has shed new light on the deaths of nearly 500 young Australians and New Zealanders who died from sudden cardiac death in a three-year period, the New England Journal of Medicine reports today.
A personalized virtual heart predicts the risk of sudden cardiac death
A research team has developed a non-invasive 3-D virtual heart to help doctors determine who faces the highest risk of a life-threatening arrhythmia and would benefit from a defibrillator implant.

Related Cardiac Death Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".